Clinical Trials Directory

Trials / Completed

CompletedNCT00421135

A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Alaunos Therapeutics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.

Conditions

Interventions

TypeNameDescription
DRUGZIO-201ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.

Timeline

Start date
2006-02-01
Primary completion
2007-10-01
Completion
2007-10-01
First posted
2007-01-11
Last updated
2009-09-17

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00421135. Inclusion in this directory is not an endorsement.